ABSTRACT
Enormous strides have been made in the management of invasive fungal infections (IFIs). New drugs, randomized trials testing comparative efficacy and safety, and development of adjunctive measures to complement pharmacologic agents have combined to improve treatment outcomes. Sufficient studies have been done to allow evidence-based consensus guidelines for Candida, Aspergillus, and Cryptococcus to be developed. For other pathogens, case series with different treatment modalities permit guidance of treatment preferences. In this chapter, treatment strategies of the most common IFIs will be summarized.
